The U.S. Food and Drug Administration approved two new drugs for treatment of diabetic retinopathy in patients with diabetic macular edema.
Diabetic retinopathy is the most common ocular manifestation of diabetes and is a leading cause of blindness.
Ranizumab & aflibercept are monoclonal antibodies which act as a vascular endothelial growth factor (VEGF) inhibitors,prevent angiogenesis.
It is approved for treatment of :
1) neovascular (wet) age-related macular degeneration.
2) Macular edema due to retinal vein occlusion.
3) Diabetic macular edema
4) Diabetic retinopathy due to macular edema
It is given as intravitreal injection.
Patient should be monitored after injection for a week.
Adverse drug reactions observed most commonly are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP.
Endophthalmitis and retinal detachments may occur
Increases in intraocular pressure have been noted within 60 minutes of intravitreal injection.
A potential risk of arterial thromboembolic event after injection may occur.